Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorStagg, Helen R.
dc.contributor.authorFlook, Mary
dc.contributor.authorMartinecz, Antal
dc.contributor.authorKielmann, Karina
dc.contributor.authorAbel Zur Wiesch, Pia
dc.contributor.authorKarat, Aaron S.
dc.contributor.authorLipman, Marc C.I.
dc.contributor.authorSloan, Derek James
dc.contributor.authorWalker, Elizabeth F.
dc.contributor.authorFielding, Katherine L.
dc.date.accessioned2020-11-09T11:30:01Z
dc.date.available2020-11-09T11:30:01Z
dc.date.issued2020-11-02
dc.identifier.citationStagg , H R , Flook , M , Martinecz , A , Kielmann , K , Abel Zur Wiesch , P , Karat , A S , Lipman , M C I , Sloan , D J , Walker , E F & Fielding , K L 2020 , ' All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era ' , ERJ Open Research , vol. 6 , no. 4 , 00315-2020 . https://doi.org/10.1183/23120541.00315-2020en
dc.identifier.issn2312-0541
dc.identifier.otherPURE: 271100094
dc.identifier.otherPURE UUID: b60b2865-6b50-438f-978f-2948d271d284
dc.identifier.otherWOS: 000603682700059
dc.identifier.urihttp://hdl.handle.net/10023/20930
dc.descriptionFunding: H.R. Stagg and M. Flook are supported by the Medical Research Council (grant number MR/R008345/1). H.R. Stagg, A.S. Karat and M.C.I. Lipman are supported by the National Institute for Health Research (NIHR) Health Technology Assessment Programme, UK (grant number 16/88/06).en
dc.description.abstractAdherence to treatment for tuberculosis (TB) has been a concern for many decades, resulting in the World Health Organization's recommendation of the direct observation of treatment in the 1990s. Recent advances in digital adherence technologies (DATs) have renewed discussion on how to best address nonadherence, as well as offering important information on dose-by-dose adherence patterns and their variability between countries and settings. Previous studies have largely focussed on percentage thresholds to delineate sufficient adherence, but this is misleading and limited, given the complex and dynamic nature of adherence over the treatment course. Instead, we apply a standardised taxonomy – as adopted by the international adherence community – to dose-by-dose medication-taking data, which divides missed doses into 1) late/noninitiation (starting treatment later than expected/not starting), 2) discontinuation (ending treatment early), and 3) suboptimal implementation (intermittent missed doses). Using this taxonomy, we can consider the implications of different forms of nonadherence for intervention and regimen design. For example, can treatment regimens be adapted to increase the “forgiveness” of common patterns of suboptimal implementation to protect against treatment failure and the development of drug resistance? Is it reasonable to treat all missed doses of treatment as equally problematic and equally common when deploying DATs? Can DAT data be used to indicate the patients that need enhanced levels of support during their treatment course? Critically, we pinpoint key areas where knowledge regarding treatment adherence is sparse and impeding scientific progress.
dc.format.extent13
dc.language.isoeng
dc.relation.ispartofERJ Open Researchen
dc.rightsCopyright © ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.en
dc.subjectQR Microbiologyen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectT-NDASen
dc.subject.lccQRen
dc.subject.lccRMen
dc.titleAll nonadherence is equal but is some more equal than others? Tuberculosis in the digital eraen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.Infection and Global Health Divisionen
dc.contributor.institutionUniversity of St Andrews.School of Medicineen
dc.identifier.doihttps://doi.org/10.1183/23120541.00315-2020
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record